Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anbio Biotechnology's book value per share for the quarter that ended in Dec. 2025 was $0.69.
During the past 12 months, Anbio Biotechnology's average Book Value Per Share Growth Rate was 75.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 33.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Anbio Biotechnology was 89.10% per year. The lowest was 33.90% per year. And the median was 61.50% per year.
During the past 5 years, the highest P/B Ratio of Anbio Biotechnology was 130.26. The lowest was 13.67. And the median was 39.45.
Good Sign:
Anbio Biotechnology stock PB Ratio (=14.61) is close to 2-year low of 13.67.
Anbio Biotechnology (NAS:NNNN) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Anbio Biotechnology Book Value per Share Related Terms
Anbio Biotechnology Book Value per Share Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNNN vs ANGO, OSUR, UTMD: Book Value per Share Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a Book Value per Share of $0.69 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Anbio Biotechnology and its competitors.
Is Anbio Biotechnology's Book Value per Share too high?
Anbio Biotechnology's current Book Value per Share is $0.69. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Book Value per Share compare to ANGO and OSUR?
Anbio Biotechnology's Book Value per Share of $0.69 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Medical Devices & Instruments company?
A good Book Value per Share depends on the Medical Devices & Instruments industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Anbio Biotechnology and its competitors. Anbio Biotechnology's current Book Value per Share is $0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Book Value per Share of $0.69. The current Book Value per Share is $0.69. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Book Value per Share is $0.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
